# Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)

> **NCT03530215** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 500000 (actual)

## Conditions studied

- Cardiac Disease
- Cancer

## Interventions

- **DRUG:** Antineoplastic and Immunomodulating Agents

## Key facts

- **NCT ID:** NCT03530215
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-02
- **Primary completion:** 2022-05-01
- **Final completion:** 2023-04-08
- **Target enrollment:** 500000 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03530215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03530215, "Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03530215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*